BioSight
Companies
ALX ONCOLOGY HOLDINGS INC logo

ALXO

NASDAQSOUTH SAN FRANCISCO, CA
ALX ONCOLOGY HOLDINGS INC

ALX Oncology Holdings is a clinical-stage biotech company developing cancer immunotherapies, primarily focusing on CD47 blockade and targeted antibody-drug conjugates. Its lead candidate, evorpacept, is a CD47 blocker designed to work with other cancer treatments to help the immune system kill tumor cells, currently in Phase 2 testing for HER2-positive breast cancer. Its second candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate that entered Phase 1 trials in August 2025.

Price history not yet available for ALXO.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar